VEGF作为自体外周血干细胞移植治疗POEMS综合征患者的复发标志物和疾病强度标志物

IF 3.9 4区医学 Q2 HEMATOLOGY Hematological Oncology Pub Date : 2025-02-21 DOI:10.1002/hon.70049

Francesco Autore, Daniele Mannina, Federica Lessi, Eugenio Galli, Stefania Oliva, Daniele Derudas, Claudia Giannotta, Claudia Crippa, Katia Mancuso, Magda Marcatti, Idanna Innocenti, Rita Mazza, Stefania Bramanti, Luca Laurenti

{"title":"VEGF作为自体外周血干细胞移植治疗POEMS综合征患者的复发标志物和疾病强度标志物","authors":"Francesco Autore, Daniele Mannina, Federica Lessi, Eugenio Galli, Stefania Oliva, Daniele Derudas, Claudia Giannotta, Claudia Crippa, Katia Mancuso, Magda Marcatti, Idanna Innocenti, Rita Mazza, Stefania Bramanti, Luca Laurenti","doi":"10.1002/hon.70049","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Overproduction of vascular endothelial growth factor (VEGF) seems to contribute to the pathogenesis, still unclear, of POEMS Syndrome. Our study retrospectively reviewed the clinical and VEGF data from a multicenter Italian cohort of patients affected by POEMS syndrome who underwent to autologous peripheral blood stem cell transplantation (aPBSCT) in order to find an impact on clinical improvement or outcome. Patients with VEGF levels higher than 758 pg/mL were at higher risk of relapse, with sensible difference in PFS (<i>p</i> = 0.007). VEGF could be used as a marker of relapse and as a marker of disease intensity in patients with POEMS.</p>\n </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation\",\"authors\":\"Francesco Autore, Daniele Mannina, Federica Lessi, Eugenio Galli, Stefania Oliva, Daniele Derudas, Claudia Giannotta, Claudia Crippa, Katia Mancuso, Magda Marcatti, Idanna Innocenti, Rita Mazza, Stefania Bramanti, Luca Laurenti\",\"doi\":\"10.1002/hon.70049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Overproduction of vascular endothelial growth factor (VEGF) seems to contribute to the pathogenesis, still unclear, of POEMS Syndrome. Our study retrospectively reviewed the clinical and VEGF data from a multicenter Italian cohort of patients affected by POEMS syndrome who underwent to autologous peripheral blood stem cell transplantation (aPBSCT) in order to find an impact on clinical improvement or outcome. Patients with VEGF levels higher than 758 pg/mL were at higher risk of relapse, with sensible difference in PFS (<i>p</i> = 0.007). VEGF could be used as a marker of relapse and as a marker of disease intensity in patients with POEMS.</p>\\n </div>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":\"43 2\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-02-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.70049\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70049","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

血管内皮生长因子（VEGF）的过量产生似乎与POEMS综合征的发病机制有关，目前尚不清楚。我们的研究回顾性回顾了意大利多中心POEMS综合征患者的临床和VEGF数据，这些患者接受了自体外周血干细胞移植（aPBSCT），以发现对临床改善或结果的影响。VEGF水平高于758 pg/mL的患者复发风险较高，PFS差异明显（p = 0.007）。VEGF可作为POEMS患者复发和疾病强度的标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation

Overproduction of vascular endothelial growth factor (VEGF) seems to contribute to the pathogenesis, still unclear, of POEMS Syndrome. Our study retrospectively reviewed the clinical and VEGF data from a multicenter Italian cohort of patients affected by POEMS syndrome who underwent to autologous peripheral blood stem cell transplantation (aPBSCT) in order to find an impact on clinical improvement or outcome. Patients with VEGF levels higher than 758 pg/mL were at higher risk of relapse, with sensible difference in PFS (p = 0.007). VEGF could be used as a marker of relapse and as a marker of disease intensity in patients with POEMS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.